Myriad Genetics, Inc. (NASDAQ:MYGN) updated its FY18 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $1.00-1.05 for the period, compared to the Thomson Reuters consensus estimate of $1.08. The company issued revenue guidance of $750-770 million, compared to the consensus revenue estimate of $789.30 million.Myriad Genetics also updated its Q1 guidance to $0.19-0.21 EPS.
Several equities research analysts recently weighed in on the company. Jefferies Group LLC reaffirmed a hold rating and issued a $21.00 price target (up from $18.00) on shares of Myriad Genetics in a research note on Wednesday, May 3rd. BidaskClub cut Myriad Genetics from a strong-buy rating to a buy rating in a research note on Wednesday, July 19th. Barclays PLC cut their target price on Myriad Genetics from $28.00 to $26.00 and set an equal weight rating on the stock in a research note on Wednesday, August 9th. Zacks Investment Research raised Myriad Genetics from a hold rating to a buy rating and set a $28.00 target price on the stock in a research note on Monday, July 17th. Finally, Piper Jaffray Companies reaffirmed a hold rating and set a $22.00 price objective on shares of Myriad Genetics in a research report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $21.22.
Myriad Genetics, Inc. (NASDAQ:MYGN) traded up 3.37% on Friday, hitting $28.80. The stock had a trading volume of 1,315,637 shares. The company has a market cap of $1.97 billion, a price-to-earnings ratio of 90.28 and a beta of 0.31. The company has a 50 day moving average price of $25.48 and a 200-day moving average price of $21.36. Myriad Genetics, Inc. has a 52-week low of $15.15 and a 52-week high of $29.01.
Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, August 8th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.04. Myriad Genetics had a return on equity of 9.67% and a net margin of 2.83%. The business had revenue of $200.50 million during the quarter, compared to analysts’ expectations of $193.71 million. During the same quarter in the prior year, the firm earned $0.36 earnings per share. The business’s revenue was up 7.5% compared to the same quarter last year. On average, equities research analysts predict that Myriad Genetics, Inc. will post $1.02 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Myriad Genetics, Inc. (NASDAQ:MYGN) Releases FY18 Earnings Guidance” was posted by BNB Daily and is owned by of BNB Daily. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/myriad-genetics-inc-nasdaqmygn-updates-fy18-earnings-guidance-updated.html.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.